Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Active, not recruiting · NCT02584933 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | neoplasm | Active, not recruiting | Phase 4 | 2026-09-17 | NCT02584933 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Essex Oncology of North Jersey PA | Belleville | United States | 1 |
| Highlands Oncology Group | Fayetteville | United States | 16 |
| Loma Linda University | Loma Linda | United States | 19 |
| Maryland Oncology Hematology P A | Rockville | United States | 1 |
| University of Colorado Cancer Center | Aurora | United States | 63 |